Log in

NASDAQ:CTIC - CTI BioPharma Stock Price, Forecast & News

$1.50
-0.03 (-1.96 %)
(As of 12/15/2019 06:12 AM ET)
Today's Range
$1.43
Now: $1.50
$1.93
50-Day Range
$0.72
MA: $0.85
$1.50
52-Week Range
$0.60
Now: $1.50
$1.93
Volume4.18 million shs
Average Volume527,113 shs
Market Capitalization$86.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTIC
Previous SymbolNASDAQ:CTICD
CUSIPN/A
Phone206-282-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.29 million
Book Value$0.91 per share

Profitability

Net Income$-29,320,000.00
Net Margins-177.54%

Miscellaneous

Employees46
Market Cap$86.97 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.


CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

CTI BioPharma shares reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp (NASDAQ:CTIC) issued its quarterly earnings data on Monday, November, 4th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The biopharmaceutical company had revenue of $2.29 million for the quarter. CTI BioPharma had a negative return on equity of 78.10% and a negative net margin of 177.54%. View CTI BioPharma's Earnings History.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for CTI BioPharma.

What price target have analysts set for CTIC?

3 brokers have issued twelve-month price objectives for CTI BioPharma's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate CTI BioPharma's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 166.7% from the stock's current price. View Analyst Price Targets for CTI BioPharma.

What is the consensus analysts' recommendation for CTI BioPharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CTI BioPharma.

Has CTI BioPharma been receiving favorable news coverage?

Media coverage about CTIC stock has been trending somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CTI BioPharma earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for CTI BioPharma.

Are investors shorting CTI BioPharma?

CTI BioPharma saw a increase in short interest in October. As of October 31st, there was short interest totalling 230,800 shares, an increase of 15.3% from the September 30th total of 200,200 shares. Based on an average daily trading volume, of 104,100 shares, the short-interest ratio is presently 2.2 days. Currently, 0.4% of the shares of the stock are sold short. View CTI BioPharma's Current Options Chain.

Who are some of CTI BioPharma's key competitors?

What other stocks do shareholders of CTI BioPharma own?

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the folowing people:
  • Dr. Adam R. Craig, Pres, CEO, Interim Chief Medical Officer & Director (Age 53)
  • Dr. Jack W. Singer, Co-Founder & Consultant (Age 76)
  • Mr. David H. Kirske, Exec. VP, CFO & Sec. (Age 65)
  • Mr. Bruce J. Seeley, Exec. VP & COO (Age 55)
  • Mr. Ed Bell, Sr. Director of Investor Relations

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.38%) and Squarepoint Ops LLC (0.15%). Company insiders that own CTI BioPharma stock include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma.

Which institutional investors are selling CTI BioPharma stock?

CTIC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for CTI BioPharma.

Which institutional investors are buying CTI BioPharma stock?

CTIC stock was acquired by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC. Company insiders that have bought CTI BioPharma stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for CTI BioPharma.

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $1.50.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $86.97 million and generates $26.29 million in revenue each year. CTI BioPharma employs 46 workers across the globe.View Additional Information About CTI BioPharma.

What is CTI BioPharma's official website?

The official website for CTI BioPharma is http://www.ctibiopharma.com/.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]


MarketBeat Community Rating for CTI BioPharma (NASDAQ CTIC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  223 (Vote Outperform)
Underperform Votes:  249 (Vote Underperform)
Total Votes:  472
MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote "Outperform" if you believe CTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Featured Article: 52 Week Highs

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel